Cargando…

Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial

BACKGROUND: Masitinib is an oral tyrosine kinase inhibitor that selectively targets mast cell activity and platelet-derived growth factor receptor (PDGFR) signaling, both of which are implicated in various mechanisms of asthma pathogenesis. OBJECTIVE: Assessment of masitinib as an add-on to standard...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davidescu, Lavinia, Ursol, Grigoriy, Korzh, Oleksii, Deshmukh, Vikranth, Kuryk, Lesia, Nortje, Monja-Marie, Godlevska, Olga, Devouassoux, Gilles, Khodosh, Eduard, Israel, Elliot, Moussy, Alain, Mansfield, Colin D, Hermine, Olivier, Chanez, Pascal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188333/ https://www.ncbi.nlm.nih.gov/pubmed/35698580 http://dx.doi.org/10.2147/JAA.S337284

Ejemplares similares

Neuroprotective effect of masitinib in rats with postischemic stroke
por: Kocic, Ivan, et al.
Publicado: (2014)

Long-term survival analysis of masitinib in amyotrophic lateral sclerosis
por: Mora, Jesus S., et al.
Publicado: (2021)

Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial
por: Vermersch, Patrick, et al.
Publicado: (2022)

Depression in Patients with Mastocytosis: Prevalence, Features and Effects of Masitinib Therapy
por: Moura, Daniela Silva, et al.
Publicado: (2011)

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
por: Vermersch, Patrick, et al.
Publicado: (2012)

Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
por: Dubreuil, Patrice, et al.
Publicado: (2009)

Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
por: Dubois, Bruno, et al.
Publicado: (2023)

Decrease of cocaine, but not heroin, self-administration and relapse by the tyrosine kinase inhibitor masitinib in male Sprague Dawley rats
por: Belin-Rauscent, A., et al.
Publicado: (2018)

Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model
por: Humbert, Martine, et al.
Publicado: (2010)

Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
por: Dubois, Bruno, et al.
Publicado: (2023)

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer
por: Deplanque, G., et al.
Publicado: (2015)

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study
por: Tebib, Jacques, et al.
Publicado: (2009)

More about masitinib
por: Walker, Ulrich A
Publicado: (2009)

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial
por: Piette, François, et al.
Publicado: (2011)

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial
por: Adenis, A., et al.
Publicado: (2014)

Interaction of Masitinib with Organic Cation Transporters
por: Harrach, Saliha, et al.
Publicado: (2022)

Masitinib Inhibits Hepatitis A Virus Replication
por: Sasaki-Tanaka, Reina, et al.
Publicado: (2023)

MasitinibL shows promise as a drug-like analog of masitinib that elicits comparable SARS-Cov-2 3CLpro inhibition with low kinase preference
por: Durojaye, Olanrewaju Ayodeji, et al.
Publicado: (2023)

Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro
por: Milovancev, Milan, et al.
Publicado: (2016)

ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?
por: Petrov, Dmitry, et al.
Publicado: (2017)

Development of Masitinib Derivatives with Enhanced M(pro) Ligand Efficiency and Reduced Cytotoxicity
por: Menendez, Cintia A., et al.
Publicado: (2023)

Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis
por: Trias, Emiliano, et al.
Publicado: (2016)

Medical approach to the treatment of feline injection site sarcoma with masitinib: a case report
por: Ledoux, Jean-Marie, et al.
Publicado: (2014)

Effects of Tyrosine Kinase Inhibitor-masitinib Mesylate on Canine Mammary Tumour Cell Lines
por: Ustun-Alkan, Fulya, et al.
Publicado: (2021)

Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme
por: Taillé, Camille, et al.
Publicado: (2020)

Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance
por: KATHAWALA, RISHIL J., et al.
Publicado: (2014)

Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
por: Drayman, Nir, et al.
Publicado: (2021)

How can we minimise the use of regular oral corticosteroids in asthma?
por: Bourdin, Arnaud, et al.
Publicado: (2020)

Characterization of in vivo metabolites in rat urine following an oral dose of masitinib by liquid chromatography tandem mass spectrometry
por: Kadi, Adnan A., et al.
Publicado: (2018)

Masitinib analogues with the N-methylpiperazine group replaced – A new hope for the development of anti-COVID-19 drugs
por: Gurung, Arun Bahadur, et al.
Publicado: (2023)

LC–MS/MS method for the quantification of masitinib in RLMs matrix and rat urine: application to metabolic stability and excretion rate
por: Amer, Sawsan M., et al.
Publicado: (2017)

A suitable drug structure for interaction with SARS‐CoV‐2 main protease between boceprevir, masitinib and rupintrivir; a molecular dynamics study
por: Yoosefian, Mehdi, et al.
Publicado: (2023)

Prioritising outcomes for evaluating eosinophil-guided corticosteroid therapy among patients with acute COPD exacerbations requiring hospitalisation: a Delphi consensus study
por: Suehs, Carey Meredith, et al.
Publicado: (2020)

Evaluation of health-promoting self-care behaviors in hypertensive patients with concomitant chronic kidney disease in primary care
por: Korzh, Oleksii, et al.
Publicado: (2022)

A Charter to Fundamentally Change the Role of Oral Corticosteroids in the Management of Asthma
por: Haughney, John, et al.
Publicado: (2023)

The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs
por: Gentilini, Fabio, et al.
Publicado: (2020)

The reliability of lung ultrasound in assessment of idiopathic pulmonary fibrosis
por: Manolescu, Diana, et al.
Publicado: (2018)

Antenatal corticosteroids for neonates born before 25 Weeks—A systematic review and meta-analysis
por: Deshmukh, Mangesh, et al.
Publicado: (2017)

Corticosteroid suppression of lipoxin A(4 )and leukotriene B(4)from alveolar macrophages in severe asthma
por: Bhavsar, Pankaj K, et al.
Publicado: (2010)

Behaviour of Silica and Florisil as Solid Supports in the Removal Process of As(V) from Aqueous Solutions
por: Gabor, Andreea, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_op4i5ra8konq0dini5tge43mnt